Fig. 6: Combinational effect of trastuzumab and EPZ in vivo.

a Tumor volume along treatment (left) or change (%; right) of tumor volume from baseline tumors in NCR nude mice bearing UACC812 xenografts were treated with vehicle (n = 7), EPZ (n = 8), trastuzumab (trast; n = 8), or in combination (EPZ + Trast; n = 7). EPZ was administered once per day via oral gavage at 250 mg/kg, while trastuzumab was administered once per week via intraperitoneal injection at a loading dose of 30 mg/kg and subsequently 15 mg/kg. Tumor volumes were measured twice a week. b Tumor volume along treatment (left) or change (%; right) of tumor volume from baseline tumors in NCR nude mice bearing MB361 xenografts were treated with vehicle (n = 7), EPZ (n = 6), trastuzumab (trast; n = 6), or in combination (EPZ + Trast; n = 6). EPZ was administered once per day via oral gavage at 250 mg/kg, while trastuzumab was administered once every six days via intraperitoneal injection at a loading dose of 30 mg/kg and subsequently 15 mg/kg. P values in a and b were determined by two-way ANOVA and adjusted with Bonferroni correction. c Representative images (left) and quantification (right) of IHC with tumors from a. Data were acquired with tumors from seven mice (n = 7) from each group. Scale bar: 150 µm. P values were determined with two-tailed Student’s t-test.